Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04905446 · ClinicalTrials.gov registry record · NA

Measurement of NAD+ Synthesis in Human Skeletal Muscle

A NA study, sponsored by AdventHealth Translational Research Institute.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT04905446 is a NA study that has completed, run by AdventHealth Translational Research Institute. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04905446, a NA study, has completed, sponsored by AdventHealth Translational Research Institute.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

The key objective of this pilot research study is to dose human volunteers with a heavy (non-radioactive) isotope derivative of nicotinamide to detect NAD synthesis in human skeletal muscle. The ultimate goal is to examine the impact of lifestyle choices, aging, nutraceuticals, and drugs on the rate of NAD synthesis in human subjects.

Interventions

  • PROCEDURE Skeletal muscle biopsy
  • OTHER Deuterated nicotinamide (D4-NAM) IV infusion
  • PROCEDURE Skin tissue biopsy

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-09-10
Est. Completion 2024-12-20
Phase NA

What the Registry Record Tells You About NCT04905446

The ClinicalTrials.gov registry entry for NCT04905446 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Skeletal muscle biopsy is the first listed.

NCT04905446 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04905446 about?

NCT04905446 is a clinical study titled "Measurement of NAD+ Synthesis in Human Skeletal Muscle". The key objective of this pilot research study is to dose human volunteers with a heavy (non-radioactive) isotope derivative of nicotinamide to detect NAD synthesis in human skeletal muscle. The ultimate goal is to examine the impact of lifestyle choices, aging, nutraceuticals, and drugs on the rate...

What is the current status of trial NCT04905446?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2021-09-10. Estimated completion is 2024-12-20.

What interventions are being tested in trial NCT04905446?

The interventions under investigation include: Skeletal muscle biopsy (PROCEDURE), Deuterated nicotinamide (D4-NAM) IV infusion (OTHER), Skin tissue biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT04905446?

This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.